Drugs that attack cancer cells have been and continue to be one of the most effective ways to fight cancer. Recent advances in cancer biology and molecular genetics have opened the door to a new era of drug therapy. The Chemical Therapeutics Program brings together faculty with strengths in chemistry, engineering, pharmacology, and clinical trials to translate this new knowledge about the cellular and molecular changes that drive the growth of cancer into effective chemically-based therapies. It is also home the Center’s Phase I Clinical Trials Program. As a result, the Chemical Therapeutics Program is the nidus for translational investigators working to develop and evaluate novel agents and molecular-based diagnostics for cancer. The Chemical Therapeutics Program leader is Philip Cole, M.D., Ph.D.
Physician Scientists
Laboratory Scientists
Cole, Philip, M.D., Ph.D.
Gray, Jeffrey, Ph.D.
Hanes, Justin, Ph.D.
Isaacs, John, Ph.D.
Laiho, Marikki, Ph.D.
Leahy, Daniel, Ph.D.
Liu, Jun, Ph. D.
Meyers, Caren, Ph.D.
Pandey, Akhilesh, M.D., Ph.D.
Rudek, Michelle, Ph.D., Pharm.D.
Searson, Peter, Ph.D.
Semenza, Gregg, Ph.D.
Stivers, James, Ph.D.
Taverna, Sean, Ph.D.
Wirtz, Denis, Ph.D.
Zhang, Jin, Ph.D.
Zhu, Heng, Ph.D.
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts